Marksans Pharma

Marksans Pharma Current Assets

The Current Assets of Marksans Pharma (MARKSANS.NS) as of Oct 27, 2026 is 21.74 B INR.

Current Assets

21.74 BINR

Last updated:

Current Assets of Marksans Pharma is 2025 21.74 B INR. Current Assets of Marksans Pharma was 2024 - INR. It decreases by % lower compared to the previous year.

The Marksans Pharma Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2017
4.84 B INR
Jan 1, 2018
4.51 B INR
Jan 1, 2019
5.31 B INR
Jan 1, 2020
5.90 B INR
Jan 1, 2021
9.02 B INR
Jan 1, 2022
12.01 B INR
Jan 1, 2023
16.55 B INR
Jan 1, 2025
21.74 B INR
The Marksans Pharma Current Assets history
YEARCurrent AssetsYoY
21.74 BINR+31.31%
16.55 BINR+37.82%
12.01 BINR+33.13%
9.02 BINR+52.87%
5.90 BINR+11.07%
5.31 BINR+17.95%
4.51 BINR-6.88%
4.84 BINR+9.89%
4.40 BINR+31.98%
3.34 BINR+4.32%
3.20 BINR+31.12%
2.44 BINR+13.07%
2.16 BINR+3.01%
2.09 BINR-18.14%
2.56 BINR-1.84%
2.61 BINR-11.24%
2.94 BINR-17.81%
3.57 BINR+5.03%
3.40 BINR+159.42%
1.31 BINR+32.96%
986.00 MINR+277.78%
261.00 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Marksans Pharma Stock analysis

What does Marksans Pharma do? Marksans Pharma Ltd. generates revenue through the research, manufacturing, marketing, and sale of pharmaceutical formulations across multiple therapeutic areas including pain management, cough and cold, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, hormonal treatment, and anti-allergic products. The company operates four manufacturing facilities in India, the United Kingdom, and the United States, producing oral solid tablets, soft gelatin capsules, hard capsules, non-sterile liquids, ointments, and powders. Its products are distributed to markets in the United Kingdom, West Africa, and the Middle East, with manufacturing facilities in Goa, the United Kingdom, and the United States catering to these regions. The firm's primary revenue streams come from the sale of pharmaceutical formulations manufactured at its facilities in Goa, the United Kingdom, and the United States. The company's product portfolio spans various therapeutic segments, with manufacturing capabilities for tablets, capsules, liquids, ointments, and powders. Its facilities in Goa and the United Kingdom serve the United Kingdom, West Africa, and the Middle East markets, while the U.S. facility focuses on domestic and international distribution of tablet and capsule products. Marksans Pharma Ltd. sells its pharmaceutical formulations to healthcare providers, pharmacies, and distributors across multiple regions. The company's manufacturing facilities in Goa, the United Kingdom, and the United States support its global distribution network, with specific facilities dedicated to serving the United Kingdom, West Africa, and the Middle East markets through non-sterile liquid, ointment, and powder products. The firm's product range includes pain management, cough and cold, cardiovascular, and anti-diabetic formulations, among others, sold to customers in the specified regions. Marksans Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Marksans Pharma stock

Current Assets of Marksans Pharma is 21.74 B INR in 2025.

On Eulerpool you can find the complete historical development of Current Assets Marksans Pharma since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Marksans Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Marksans Pharma

All Key Metrics — Marksans Pharma